A recent meta-analysis evaluated PD-1 and PD-L1 inhibitors’ efficacy compared to other treatments in patients with different tumors (mainly lung cancer, but also RCC, melanoma, head/neck cancer, and urothelial cancer) classified in two groups according to PD-L1 expression. The gene discussed is RPL17; the disease is renal cell carcinoma.